Day: October 20, 2022

GRAID Technology & primeLine Solutions

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — primeLine Solutions GmbH, a leader in German tailor-made high performance servers, now incorporates SupremeRAID GPU accelerated RAID as part of its custom NVMe storage offerings — delivering sophisticated software-composed data protection and impressive performance for demanding workloads.

Fusion vessel trial ring

Construction of General Fusion’s demonstration machine, which is being built at the UK Atomic Energy Agency’s Culham Campus, advanced significantly with the fabrication of an at-scale fusion vessel trial ring by Sheffield Forgemasters

VANCOUVER, British Columbia and LONDON, Oct. 20, 2022 (GLOBE NEWSWIRE) — Construction of General Fusion’s demonstration machine, which is being built at the UK Atomic Energy Agency’s Culham Campus, advanced significantly with the fabrication of an at-scale fusion vessel trial ring by Sheffield Forgemasters.

This critical component will confirm the specifications of the thick-walled fusion vessel, designed to withstand the high temperatures and compressive forces needed to create fusion energy with General Fusion’s practical technology – Magnetized Targeted Fusion (MTF).

The vessel is designed to be modular, made up of 11 steel rings bolted together on site. In the future, this cost-effective and efficient method will enable General Fusion to deploy its commercial machines quickly.

The trial ring’s specifications are the same as the rings planned for the fusion demonstration machine and allow the engineering team to validate the performance of the high-strength steel alloy, finalize the vessel design, and confirm the manufacturing process.

The fusion demonstration machine will create fusion conditions, including achieving a temperature of 100 million degrees Celsius in a power-plant-relevant environment. Its results will provide the information needed to design and build a commercial pilot plant that generates electricity at an affordable price.

“Sheffield Forgemasters brings to this project over 200 years of expertise creating complex steel components,” said Greg Twinney, Chief Executive Officer, General Fusion. “Teaming up with world-leading specialists allows us to focus on our commercialization plan and stay on pace to generate zero-carbon electricity by the early 2030s.”

“At Sheffield Forgemasters, we pride ourselves on our innovation and have extensive knowledge and experience in establishing practical manufacturing solutions for disruptive technologies, such as fusion energy,” said David Bond, Chief Executive Officer, Sheffield Forgemasters. “We are thrilled to be a part of this project and to play a role in bringing fusion energy to the world.”

To create the trial ring, a large steel ingot was forged in an open-die press, forming the steel into a donut shape with a diameter of just over three metres. Next, the ingot will be rolled and expanded into a larger, thinner ring; at this point, the ring will span 7.6 metres in diameter. Then, 56 holes will be drilled into the ring. These replicate the holes that will transmit high-pressure gas from the compression drivers to a spinning interior rotor in the fusion demonstration machine. The pressure change will push smaller pistons to collapse General Fusion’s proprietary liquid metal liner around hydrogen plasma and create fusion.

The final trial ring will weigh an impressive 42 metric tons. Sheffield Forgemasters’ engineering team will complete non-destructive testing on the trial ring, which can include visual, ultrasonic, dye-penetrant and magnetic particle inspection, as well as eddy current testing.

“At General Fusion, every decision we make is guided by our mission to bring affordable fusion energy to the electricity grid in a practical way. Projects such as this cultivate our fusion supply chain and show that the time for fusion energy is now,” said Mr. Twinney.

About General Fusion
General Fusion is pursuing the fastest and most practical path to commercial fusion energy and is based in Vancouver, Canada, with locations in London, UK, and Oak Ridge, Tennessee, USA. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.

General Fusion Media Relations
media@generalfusion.com
+1-866-904-0995

Follow General Fusion
twitter.com/generalfusion
instagram.com/generalfusion
linkedin.com/company/general-fusion
facebook.com/generalfusion
youtube.com/c/GeneralFusionInc

About Sheffield Forgemasters
Sheffield Forgemasters specialises in the design and manufacture of high-integrity forgings and castings for the world’s most complex engineering challenges.

The company operates a fully integrated end-to-end manufacturing process, including steel-making, forge, foundry, machining and testing, from a single site in Sheffield. Some of the largest bespoke engineered steel products in the world are produced with capacity for castings of up to 350 tonnes and forgings of up to 200 tonnes finished weight.

Global markets served include Defence, Civil Nuclear, Offshore, Power Generation, Renewables, Steel Plant, Steel Processing and Ingot & Bar.

The company was acquired in August 2021 by the Ministry of Defence who intend to invest up to £400m over the next 10 years to re-capitalise defence-critical plant and equipment on site.

For further information, contact Agent Public Relations – Billy Greenhalgh on 07730527270 www.agentpr.co.uk.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ed65e50a-24bf-4605-89d1-e8f089ef5950

SEATTLE and SINGAPORE, Oct. 20, 2022 (GLOBE NEWSWIRE) —  Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a leading digital financial services provider for immigrants and their families in over 170 countries around the world, today announced key business milestones in the Asia-Pacific (APAC) region. Remitly has expanded its global footprint to include Japan and New Zealand. To date, Remitly has helped customers send $2.5 billion in remittance volume from APAC, and the company is poised for further growth as access to its trusted platform becomes available to millions of new customers in the region.

According to the World Bank, remittances sent from Japan have doubled since 2015 to $8.25 billion in 2020. Additionally, personal remittances sent from New Zealand nearly quadrupled over the past 20 years, totaling close to $875 million. Once Remitly’s new APAC send corridors are operational, customers in Japan and New Zealand will be able to send money across more than 150 corridors using Remitly’s mobile-centric suite of products and best-in-class global network, providing customers and their loved ones a range of disbursement options to meet their specific needs.

“Remitly is proud to serve immigrants living in Asia and the greater Pacific region and to leverage the investments we’ve made in our global payments platform to be the trusted provider for customers sending money home to their loved ones,” said Matt Oppenheimer, co-founder and CEO, of Remitly. “We are on a mission to transform international payments. Helping customers send more than $2.5 billion from the region to date is a testament not only to strong demand, but also to the world-class customer experience Remitly provides, making the process of getting money home faster, simpler, and more reliable.”

“Remitly’s strategic approach to expansion leverages the significant payments infrastructure we’ve built over more than a decade, and is underpinned by our commitment to customers around the world,” said Pankaj Sharma, Executive Vice President, International at Remitly. “Establishing business in Japan and New Zealand will open key corridors as we thoughtfully expand our platform to meet increasing customer demand for trusted financial services”

Remitly’s expansive disbursement network reaches 3.9 billion bank accounts, 705 million mobile wallets, 410,000 cash pickup locations, and offers home delivery in select locations. The best-in-class global network provides an exceptional customer experience, including faster transfers, higher acceptance rates, and improved reliability. While the footprint of the platform continues to grow to more than 3,200 corridors, service is localized for a more personal, differentiated customer experience.

For more information about Remitly, please visit www.remitly.com. To learn more about job opportunities in the region, go to our careers site.

About Remitly

Remitly is a leading digital financial services provider for immigrants and their families in over 170 countries around the world. Remitly helps immigrants send money home in a safe, reliable and transparent manner. Its digitally-native, cross-border remittance app eliminates the long wait times, complexities and fees typical of traditional remittance processes. Building on its strong foundation, Remitly is expanding its suite of products to further its mission and transform financial services for immigrants all around the world. Founded in 2011, Remitly is headquartered in Seattle and has seven global offices, including London, Cork, Singapore, Manila and Managua.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements are based on current expectations, including, but not limited to, statements regarding Remitly’s operational expansion into Japan and New Zealand. Actual results may differ materially from expectations discussed in such forward-looking statements. Factors that might cause such differences include, but are not limited to, risks to our business and operating results related to the COVID-19 pandemic; the current inflationary environment; foreign currency exchange rate fluctuations; unanticipated costs or difficulties relating to the integration of companies we have acquired or will acquire into Remitly; competition from existing and new competitors. In particular, see recent and upcoming Remitly quarterly and annual reports filed with the Securities and Exchange Commission, copies of which are available upon request from Remitly. Remitly does not assume any obligation to update the forward-looking information contained in this press release.

Media Contact:
Adam Cormier
adamc@remitly.com

Investor Relations:
Stephen Shulstein
stephens@remitly.com

Nuvei brings new instant settlement options to merchants globally, aiding regions where instant account-to-account payment solutions are not available

Montreal, Oct. 20, 2022 (GLOBE NEWSWIRE) — Nuvei Corporation (“Nuvei” or the “Company”) (Nasdaq: NVEI) (TSX: NVEI), the Canadian fintech company, announces today that its merchant client base can now benefit from instant settlement globally and around the clock in EUROC and USDT stablecoins.

Fast liquidity is a real revenue accelerator for businesses. While merchants in many countries benefit from instant settlement through various payment schemes such as Instant SEPA, RTP or Faster Payments, alternatives are not always available in all corners of the world. That is where stablecoins come in.

Stablecoins are price-stable digital currencies backed by a fiat currency such as the Euro or US Dollar. Because they combine the benefits of open, borderless cryptocurrency with the price stability of traditional currencies, stablecoins provide new ways to support corporate finance and working capital management.
“The addition of settlement through the EUROC and USDT stablecoins helps merchants build their next-generation payment treasury,” said Nuvei President Yuval Ziv. “Stablecoins can be transacted by utilizing the blockchain making global cashflow easier to manage,” he added.

Nuvei already offers its merchants instant settlement in locations where Instant SEPA, RTP and Faster Payments are available in fiat currencies. But for those merchants trading on the blockchain or those located in regions where these options are not available, settlement in USDT and EUROC stablecoins provides a much needed, viable alternative.

“Providing instant settlement for merchants is part of the broader real-time payments initiatives designed to shape the future of payments,” said Ziv. “With instant settlement now possible globally, around-the-clock and also in EUROC and USDT stablecoins, we’re staying true to our mission of helping merchants accelerate their business through payments.”

About Nuvei 

Nuvei (Nasdaq: NVEI) (TSX: NVEI) is the Canadian fintech company accelerating the business of clients around the world. Nuvei’s modular, flexible and scalable technology allows leading companies to accept next-gen payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in more than 200 markets, with local acquiring in 45+ markets, 150 currencies and more than 570 alternative payment methods, Nuvei provides the technology and insights for customers and partners to succeed locally and globally with one integration.

For more information, visit www.nuvei.com.

The company offers innovative and accessible diagnostic solutions that improve IVF success rates

Inti Labs logo

Inti Labs logo

PALO ALTO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Inti Labs, Inc. (Inti Labs) today announces its official launch and ambitious long-term vision to overcome infertility. The company is focused on developing a range of first-in-class diagnostic tests for the in vitro fertilization (IVF) market. Their tests are aimed at reducing the number of IVF treatment cycles a patient must go through to become pregnant, easing the financial burden on families and increasing the successful turnover at fertility clinics.

The global fertility rate has steadily declined over the years, as more women delay motherhood. Those who choose to have children later often must rely on assisted reproductive technology (ART) such as IVF. While the technology has seen significant improvement in recent years, most women must still go through multiple IVF treatment cycles to obtain a viable pregnancy. In the U.S., a single IVF treatment cycle can cost over $20,000 and is rarely covered by insurance.

“IVF is both financially and emotionally burdensome,” said Inti Labs CEO Dr. Eric Pok Yang, “but new technologies in reproductive medicine can help more women have successful pregnancies with fewer IVF cycles. Inti Labs is focused on making those technologies accessible to hopeful parents across the globe.”

Ambitious to lead the IVF diagnostics market, Inti Labs has launched its award-winning endometrial status test, MIRA®. Already in use at more than 70 institutions worldwide, with ongoing expansion across Europe, the U.S. and Southeast Asia, MIRA® uses unique miRNA biomarkers to more accurately identify a woman’s window of implantation (WOI), the optimal time for embryo transfer. About 30% of women suffering from infertility have a displaced WOI, which, if not factored in during an IVF treatment cycle, can lead to an unsuccessful attempt.

Among those joining Inti Labs’ team is Dr. Barry Behr, fulfilling the role of Chief Technology Officer (CTO). Dr. Behr is a Stanford University Professor Emeritus, where he served as Director of the IVF Laboratory and Professor of Obstetrics and Gynecology. A leading expert in the IVF field, his embryo research has directly led to improved implantation and pregnancy rates.

“With our cutting-edge technology for improved WOI assessment and gamete selection,” said Dr. Behr, “we foresee a not-too-distant future in which a perfect embryo can be reliably achieved in the first IVF cycle. That means one sperm, one egg, and one implantation to deliver a healthy baby.”

Considering MIRA®’s promising early success and other tests nearing the prototype phase, Inti Labs believes IVF will become increasingly reliable and affordable to women everywhere, as we work towards a future where infertility is no longer an insurmountable obstacle.

—

Inti Labs will be attending the 2022 ASRM Scientific Congress & Expo Oct 24-26 in Anaheim, CA, and invites you to visit their booth (#1433).

Contact Information:
Jesse Prent
Marketing Director
jesse@intilabs.com
(438) 405-1050

Tiffany Wang
Global Business Development Director
tiffany@intilabs.com

Related Images

Image 1: Inti Labs logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Inti Labs logo

GlobeNewswire Distribution ID 8668901

October 20, 2022

• FDA 510(k) clearance for AI-enabled Philips MR for Calculating Attenuation (MRCAT) Head and Neck radiotherapy application expands range of MR-only workflows
• MacroMedics’ positioning mask system [1] now compatible with Philips MR Head Neck Coil, helping to improve patient experience and treatment outcomes

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company’s artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available in the U.S.

As a result of a recent development partnership with patient-positioning company MacroMedics, Philips has also announced compatibility of MacroMedics’ latest DSPS (Double Shell Positioning System) Prominent^TM positioning system [1] with Philips MR Head Neck Coil.  This unique solution combines the superior soft tissue imaging capabilities and the high-resolution image quality of Philips’ head and neck coil with the comfort-enhancing and positional accuracy and stability features of MacroMedics’ mask. These developments aim to improve the accuracy of radiotherapy planning and simulation to help achieve better patient outcomes, enhance patient comfort, and offer the efficiency benefits of an MR-only workflow.

“With this innovative mask that fits into Philips’ head coil, we expect to acquire head and neck images for radiotherapy planning with diagnostic image quality and improved patient comfort,” said Marielle Philippens, Associate Professor, MRI for Radiotherapy at University Medical Center Utrecht (Utrecht, The Netherlands), who is currently using the integrated Philips and MacroMedics solution.

“The superior soft tissue imaging of MR together with advances in the integration and orchestration of data, including the use of artificial intelligence, promise greater clarity and less subjectivity in planning radiotherapy for head and neck cancer,” said Ilya Gipp, Chief Medical Officer Oncology Solutions at Philips. “Our collaboration with MacroMedics to develop a patient-friendly mask system compatible with our high-resolution dStream imaging coils highlights Philips’ commitment to providing the precision tools needed for the localization and characterization of difficult-to-treat tumors.”

Philips’ radiation oncology portfolio is designed to provide greater clarity by empowering oncologists with accurate image guidance, integrated workflows, and the versatility to deliver the precise, adaptive, personalized treatment every patient deserves. The company’s products and services are enhanced through strategic clinical and technology partnerships, vendor-neutral device integration, advanced imaging and AI algorithms to help physicians deliver more confident diagnoses and treatment pathways for patients.

During ASTRO 2022, Philips will also highlight its strategic partnership with Elekta in precise and personalized oncology care. Building on their successful collaboration to develop Elekta Unity, the world’s first high-field MR-linac (linear accelerator), the two companies are collaborating to further deliver image-guided adaptive treatment and oncology informatics solutions to personalize and improve cancer care.

Philips is showcasing its latest innovations in radiation oncology at ASTRO 2022 (October 23-26, San Antonio, Texas, U.S.), all of which are designed to help increase accuracy across imaging, planning, and treatment; improve patient and staff satisfaction; accelerate time to treatment; and maximize investment value. Visit Philips at ASTRO 2022 for more information on Philips’ radiation oncology innovations being highlighted at the event. Join Philips in Booth #2761 and follow @PhilipsLiveFrom for #ASTRO22 updates throughout the event.

[1] Pending FDA 510 (k) clearance; not for sale in the U.S.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• MacroMedics Product Shot
• MacroMedics mask being used in radiotherapy

GlobeNewswire Distribution ID 1000751979

– First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties —

– Introduction of BPT323, a cutting-edge, multifunctional immunocytokine combining TNFα blockade and selective T_reg expansion for the treatment of autoimmune disease —

SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10^th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.

“We are excited to share, for the first time, details of our innovative IL-2-based therapeutics that selectively activate and enhance Treg expansion for the treatment of patients with autoimmune diseases,” said Dr. Bertolt Kreft, Chief Scientific Officer of Bright Peak Therapeutics. Tregs are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory diseases. IL-2 is an essential cytokine critical for Treg activation and proliferation, and low-dose IL-2 has demonstrated promising preliminary clinical efficacy in several autoimmune diseases.

Dr. Kreft continued, “Our chemical protein synthesis platform enabled us to create an optimized IL-2 payload that is uniquely IL2Rα-enhanced as well as IL2Rβ-dead, with the further capacity to be chemically conjugated. Using this fully synthetic IL-2 payload, we created a PEGylated, half-life-extended molecule with best-in-class preclinical properties as well as a cutting-edge multifunctional immunocytokine combining TNFα blockade and selective Treg expansion.”

Details of the abstracts are as follows:

Dates and Times: October 21-24, 2022, 10:00 AM – 11:30 AM (CET)

Title: Identification of BPT264 – a potent alpha-enhanced/beta-dead and half-life-extended IL-2 Treg enhancer for treatment of autoimmune diseases

Abstract Highlights: Using our chemical protein synthesis technology, we rationally designed an enhanced cytokine payload harboring a site-specific chemical conjugation handle and specific sequence variations that retune the biological properties of IL-2 for the treatment of patients with autoimmune disease. Bright Peak’s optimized cytokine payload is engineered to uniquely augment binding to IL2Rα and ablate binding to IL2Rβ for the precise and potent activation of Treg over other immune cell types. Conjugation to a 30 kDa PEG generates a fully synthetic cytokine with optimal pharmacokinetic properties that is able to selectively expand Tregs in cynomolgus monkeys up to 60-fold and to strongly suppress antigen-specific T cell-mediated inflammation in mice. Based on these best-in-class properties, IND-enabling studies have been initiated and a first in human trial is planned to start early 2024.

Title: Identification of BPT323 – An immunocytokine for treatment of autoimmune diseases combining orthogonal modes of action of TNFα blockade and selective Treg expansion

Abstract Highlights: Bright Peak has developed a cell-free chemical protein synthesis and conjugation platform to rapidly generate optimized antibody-cytokine (immunocytokine, IC) therapeutics within weeks. We have site-specifically conjugated a single IL-2 variant that selectively activates and expands Tregs to the Fc region of the well-characterized anti-TNFα antibody adalimumab to generate an anti-TNFα-IL2 IC that fully retains the functions of the parent molecules in vitro and in vivo. TNFα-IL2 IC is apparently able to leverage an additional mode-of-action as its ability to activate and expand Tregs is augmented in the presence of TNFα. This suggests that TNFα-IL2 IC may exhibit higher local activity in inflamed tissues where TNFα is present at high levels.

The abstracts are available for viewing on Bright Peak’s website, www.brightpeaktx.com, and online at:

https://www.aegeanconferences.org/src/App/sessions/posters/155

About Bright Peak Therapeutics

Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We are rapidly advancing a robust portfolio of next generation, multifunctional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:

info@brightpeaktx.com